The role of immune checkpoint inhibitors in the first-line treatment for patients with advanced biliary tract cancer: a systematic review and meta-analysis of randomized trials
Open Access
- 18 July 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1409132
Abstract
Background: We performed a systematic review and meta-analysis to further explore the impact of the addition of immunotherapy to gemcitabine–cisplatin as first-line treatment for advanced biliary tract cancer (BTC) patients.Methods: Literature research was performed, and hazard ratio values and 95% confidence intervals were calculated. Heterogeneity among studies was assessed using the tau-squared estimator . The total Cochrane Q test (Q) was also assessed. The overall survival rate, objective response rate, and progression-free survival in the selected studies were assessed.Results: A total of 1,754 participants were included. Heterogeneity among the studies selected was found to be non-significant (p = 0.78; tau2 = 0, I2 = 0%). The model estimation results and the forest plot suggested that the test for the overall effect was significant (Z = −3.51; p< 0.01).Conclusion: The results of the current meta-analysis further confirm the role of immune checkpoint inhibitors plus gemcitabine–cisplatin as the new standard first-line treatment for advanced BTC patients.Systematic review registration: https://www.crd.york.ac.uk/prospero, identifier CRD42023488095.
Keywords
This publication has 35 references indexed in Scilit:
- Current progress in perioperative chemotherapy for biliary tract cancerAnnals of Gastroenterological Surgery, 2023
- Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancerCancer Medicine, 2022
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studiesInternational Journal of Cancer, 2020
- Cancer immunotherapy: Pros, cons and beyondBiomedicine & Pharmacotherapy, 2020
- Immunogenic cell death in anticancer chemotherapy and its impact on clinical studiesCancer Letters, 2018
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsCancer Cell, 2015
- Descriptive epidemiology of cholangiocarcinoma in ItalyDigestive and Liver Disease, 2010
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010